Eprosartan Mesylate(ep row sar’ tan)
Teveten
PREGNANCY CATEGORY D
Drug Classes
Antihypertensive
ARB
Therapeutic Actions
Selectively blocks the binding of angiotensin II to specific tissue receptors found in the vascular smooth muscle and adrenal gland; this action blocks the vasoconstriction effect of the renin–angiotensin system as well as the release of aldosterone leading to decreased BP.
Indications
Treatment of hypertension, alone or in combination with other antihypertensive drugs, particularly diuretics and calcium channel blockers
Unlabeled uses: Heart failure, left ventricular hypertrophy, diabetic nephropathy
Contraindications and Cautions
Contraindicated with hypersensitivity to any ARB, pregnancy (use during the second or third trimester can cause injury or even death to the fetus), lactation.
Use cautiously with renal impairment, hypovolemia, hyperkalemia.
Available Forms
Tablets—400, 600 mg
Dosages
Adults
Usual starting dose is 600 mg PO daily. Can be administered in divided doses bid with a total daily dose of 400–800 mg/day being effective. Patients with moderate and severe renal impairment, maximum dose is 600 mg/day. If used as part of combination therapy, eprosartan should be added to established dose of other antihypertensive, starting at the lowest dose and increasing dosage based on patient response.
Pediatric patients
Safety and efficacy not established.
